Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Company Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $109.40, for a total value of $2,188,000.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $83,995,132. This trade represents a 2.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.58, for a total value of $2,191,600.00.
• On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00.
• On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00.
• On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00.

Halozyme Therapeutics Stock Performance

HALO stock opened at $109.84 on Friday. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $116.85. The business has a 50-day moving average price of $105.64 and a 200 day moving average price of $82.86. The company has a market capitalization of $12.47 billion, a P/E ratio of 32.79, a PEG ratio of 0.42 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of HALO. GAMMA Investing LLC increased its position in shares of Halozyme Therapeutics by 22.4% during the third quarter. GAMMA Investing LLC now owns 5,493 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 1,006 shares in the last quarter. CoreCap Advisors LLC boosted its position in shares of Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 150 shares in the last quarter. MRA Advisory Group purchased a new position in Halozyme Therapeutics during the 3rd quarter worth $741,000. Congress Asset Management Co. grew its stake in Halozyme Therapeutics by 85.6% during the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after buying an additional 1,052,509 shares during the last quarter. Finally, Cim Investment Management Inc. increased its position in Halozyme Therapeutics by 7.4% during the 2nd quarter. Cim Investment Management Inc. now owns 9,121 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 629 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on HALO shares. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. TD Cowen upped their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $94.00.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: A Dutch patent court found Merck’s subcutaneous Keytruda infringed a Halozyme patent and ordered MSD to stop manufacturing, selling, importing, or stocking the product in eight European markets: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The ruling could protect Halozyme’s intellectual-property position and potential royalty economics. Halozyme Wins Injunction Stopping Manufacture and Sale of Merck’s Keytruda SC in Multiple European Markets
• Positive Sentiment: Halozyme expanded its ENHANZE collaboration with argenx to cover two additional exclusive targets, bringing the total to eight. The agreement increases the opportunity for future development milestones and royalties and supports Halozyme’s recurring revenue growth. HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
• Neutral Sentiment: The Keytruda decision is a significant win, but the ongoing patent dispute, possible appeals, and the timing of any commercial impact create uncertainty around how quickly the ruling will translate into financial results.
• Negative Sentiment: JPMorgan raised its HALO price target from $70 to $78 but maintained a “neutral” rating. The new target implies roughly 29% downside from the referenced $109.84 price, signaling concern that the stock’s valuation already reflects much of its growth and legal upside. JPMorgan Raises Halozyme Price Target

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.